Final answer:
Etanercept, an immunosuppressive medication, does not directly cause hypoglycemia, hyperglycemia, lipodystrophy, or ketoacidosis, but diabetic patients on etanercept should be monitored for infections.
Step-by-step explanation:
The client with diabetes mellitus who is taking etanercept is at an increased risk for infections due to the immunosuppressive effects of the drug. Neither hypoglycemia, hyperglycemia, lipodystrophy, nor ketoacidosis are directly associated with etanercept, which is a medication primarily used to treat autoimmune conditions by inhibiting tumor necrosis factor. Instead, it is crucial to monitor diabetic patients for signs of infection and to manage their blood glucose levels according to individualized treatment plans.